Guangzhou LBP Medicine Science & Technology Co., Ltd. (SHSE: 688393)
Health Care · Health Care Equipment & Supplies · CN
CN¥22.17
-1.25% today · -16.2% 1Y
Guangzhou LBP Medicine Science & Technology Co., Ltd. (SHSE: 688393) operates in the Health Care Equipment & Supplies industry within the Health Care sector. The company is valued at $309.70M and employs 768 people.
Over the last twelve months the share price has lost 16.2%, trading between 15.70 and 38.96.
Tweenvest scores Guangzhou LBP Medicine Science & Technology Co., Ltd. across four factors: quality 68/100, value 43/100, growth 24/100, dividend 15/100. Its strongest factor is quality.
688393 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $309.70M
- Revenue (TTM)
- $52.49M
- P/E
- —
- EPS
- -0.40
- Dividend yield
- 0.45%
- Beta (5Y)
- 0.47
- 52-week high
- CN¥38.96
- 52-week low
- CN¥15.70
- Avg volume (3M)
- —
- Shares outstanding
- 93.57M
- Employees
- 768
- Next earnings
- —
About Guangzhou LBP Medicine Science & Technology Co., Ltd.
Guangzhou LBP Medicine Science & Technology Co., Ltd. specializes in the development and manufacture of innovative pathological diagnostic solutions for the Chinese market. Its comprehensive product portfolio includes advanced pathological diagnostic reagents and essential ancillary equipment. Among these are liquid-based cytology (LBC) offerings, encompassing both gynecological and non-gynecological series, complemented by specialized equipment. The company also provides fluorescence in situ hybridization (FISH) products, which are applied across a broad spectrum of conditions. These applications range from various cancers, including breast, bladder, lung, cervical, prostate, and thyroid, to other complex diagnoses such as neuroblastoma, soft tissue sarcoma, diverse solid tumors, prenatal screening, complications in abortion, oligodendrocytes tumors, lymphoma, multiple myeloma, and several forms of leukemia (chronic myelogenous, chronic lymphocytic, acute myeloid, and acute lymphoblastic), as well as myelodysplastic syndromes. Furthermore, GLBP offers immunohistochemistry (IHC) products, comprising a range of antibodies, advanced detection and repair systems, complementary products, and complete IHC kits. Additionally, its capabilities extend to molecular genetic diagnosis products. Established in 2005, Guangzhou LBP Medicine Science & Technology Co., Ltd. is headquartered in Guangzhou, China.
- ISIN
- CNE1000043R4
- Founded
- 2005
- Listed since
- Aug 20, 2020
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Health Care Equipment & Supplies companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Embecta Corp.NasdaqGS: EMBC | $322.11M | $6.08 | +6.95% |
| ClearPoint Neuro, Inc.NasdaqCM: CLPT | $319.68M | $10.28 | -1.91% |
| Nagaileben Co., Ltd.TSE: 7447 | $312.72M | ¥1,684.00 | -1.17% |
| Stratec SEXTRA: SBS | $311.69M | €23.40 | +2.18% |
| Shanghai Rendu Biotechnology Co., Ltd.SHSE: 688193 | $298.16M | CN¥51.50 | -1.32% |
| Dirui Industrial Co.,Ltd.SZSE: 300396 | $296.80M | CN¥7.29 | +2.97% |
| Sichuan Gangtong Medical Equipment Group Co., LtdSZSE: 301515 | $289.79M | CN¥20.21 | -1.51% |
| Touchstone International Medical Science Co., Ltd.SHSE: 688013 | $286.95M | CN¥24.00 | -3.26% |
Figures last refreshed Oct 11, 2026.